ClinicalTrials.Veeva

Menu

Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia (CALIF)

C

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Status

Terminated

Conditions

Febrile Neutropenia, Drug-Induced

Treatments

Diagnostic Test: Value of ProCalcitonin

Study type

Interventional

Funder types

Other

Identifiers

NCT03182465
2017/24FEV/112

Details and patient eligibility

About

CALIF study is a monocentric observational study which aim is to analyse the value of adding procalcitonin (PCT, a pre-hormon increased in bacterial infection and septicaemia) in the management of chemo-induced febrile neutropenia occurring in patient with solid tumour. Febrile neutropenia will be managed according to international guidelines. PCT will be dosed at initial presentation. Primary objective is to determine the optimal value of PCT for the detection of septicaemia in low risk (according to MASCC score). The investigators plan also to compare two risk stratification scores: the validated MASCC score and a recently developed score which includes PCT and other more objective items.

Enrollment

54 patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • more than 18 years old
  • Patients with solid malignant tumor treated by chemotherapy (neoadjuvant, concomittant, adjuvant or metastatic)
  • Febrile neutropenia chemo-induced (fever > 38°C, neutrophils < 500 /microliter or nadir < 500 /microliter)
  • Patients non hospitalized at the event (when he presented febrile neutropenia)
  • Informed consent signed

Exclusion criteria

  • Thyroid medullar carcinoma
  • Patient not able to understand protocol (mental retardation, psychiatric disorders, .... )

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

54 participants in 1 patient group

the predictive value of ProCalcitonin
Other group
Description:
Patients with solid tumors admitted at the emergency care presenting a febrile neutropenia due to chemotherapy
Treatment:
Diagnostic Test: Value of ProCalcitonin

Trial contacts and locations

1

Loading...

Central trial contact

Gaetan Catala, MD; Jean-Pascal Machiels, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems